Astellas Pharma Inc.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.
The item "Short-Term-Debt" stands at 331.41 Billion Japanese Yens as of 06/30/2025.
As of the end of Astellas Pharma Inc.'s first quarter, the item "Short Term Debt" stands at 331.41 Billion JPY. This represents an increase of 24.34 percent compared to it's value at the end of it's fourth quarter of the company's last fiscal year.
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -39.70 percent compared to the value the year prior.
The 1 year change in percent is -39.70.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Short Term Debt | 905,699,262,464.00 |
![]() | Johnson & Johnson - Short Term Debt | 486,508,953,600.00 |
![]() | AbbVie Inc - Short Term Debt | 399,570,305,024.00 |
![]() | Roche Holding AG - Short Term Debt | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Short Term Debt | 280,205,508,085.11 |